Seres Therapeutics Inc. - MCRB Earnings per one share for the last 12 months

Official company branding of Seres Therapeutics Inc. (MCRB)

Seres Therapeutics (MCRB) is a biotech player focusing on gut microbiome treatments to combat severe infections. This EPS price action chart confirms its status as a segment leader, driven by the first FDA-approved oral drug developed in US centers. The current figure stands at -891.80. The company has now pivoted to the organic development of early-stage projects following the strategic sale of its primary commercial asset.

Seres Therapeutics, Inc. (MCRB): Net earnings per share (EPS TTM) from 02/11/2024 to 11/18/2026

serestherapeutics.com - analytical breakdowns and key metrics (MCRB)

- share price and consensus valuation forecast:
- issuer market value details:
Initial company analysis:MCRB, Seres Therapeutics Inc.
Manufactured products of Seres Therapeutics

This indicator captures the earnings per share (EPS) dynamics over a rolling year, neutralizing quarterly reporting gaps. By analyzing the current EPS YoY TTM growth rate, an investor determines the actual speed of business scaling and the risk of overheating. A positive trend confirms the issuer's financial stability. For Seres Therapeutics (MCRB), the growth of this metric is driven by strong pricing power and inelastic demand for the unique drug Vowst.